#Canada #Laval #Bausch Health #ARESTIN #OraPharma

25 Years of ARESTIN®: A Milestone in Periodontal Treatment

Bausch Health Companies Inc., through its dental products division, OraPharma, proudly celebrates the 25th anniversary of its flagship product, ARESTIN® (minocycline HCl) Microspheres. Introduced as a vital adjunct to scaling and root planing (SRP) for managing periodontitis, ARESTIN has transformed dental practices and patient outcomes over the years.

Origins and Development

The inception of ARESTIN stemmed from an urgent need in the dental community. It was conceptualized by clinicians who recognized that periodontal disease is a persistent bacterial condition that required specific remedial measures. According to Dan Wu, Ph.D., Senior Director of Pharmaceutical Sciences Technology at Bausch Health, the product aimed to fill a gap in periodontal treatment, providing an innovative method of delivering antibiotic therapy directly to affected areas.

The microspheres utilized in ARESTIN are designed to biodegrade gradually, releasing the antibiotic over time, significantly enhancing its effectiveness in reducing pocket depth for patients with periodontitis. This unique delivery mechanism underscores its status as the only FDA-approved locally applied antibiotic for this purpose, supported by over two decades of clinical experience.

The Impact of Periodontal Disease

Periodontal disease continues to be a pressing health issue, with over one billion people worldwide affected by this chronic condition. The strategic integration of ARESTIN with standard SRP procedures by dental professionals has led to enhanced treatment success rates, promoting better oral health among patients.

Celebration and Looking Ahead

Reflecting on the significance of this milestone, Tom Stern, Vice President and General Manager of the OraPharma division, affirmed the commitment to advancing periodontal care. He stated, "Reaching Arestin's 25-year milestone reflects our commitment to periodontal care, and we are equally focused on the future of innovation in collaboration with the dental community."

Moreover, OraPharma's recent commercial expansions into Canada and Puerto Rico demonstrate their commitment to ensuring access to effective treatment solutions where they are much needed.

Understanding ARESTIN and Its Importance

ARESTIN® is classified as a locally applied antibiotic utilized in conjunction with SRP procedures, targeting patients diagnosed with adult periodontitis. Its implementation is designed to work alongside good dental hygiene practices, including brushing and flossing, thereby ensuring comprehensive oral health management.

Important Safety Information

While ARESTIN offers significant benefits, it is crucial for those considering its use to be aware of specific safety guidelines. Patients allergic to minocycline or tetracyclines are advised against its use. Additionally, it is not recommended for children or pregnant/nursing women due to potential risks linked to tooth development.

Patients should also be cautious about sun exposure while using ARESTIN, as sensitivity to sunlight may result in severe burns. Monitoring for allergic reactions, such as difficulty breathing or swelling, is paramount, and patients should communicate their complete medical history to their dentist before usage.

The Legacy of Bausch Health

Bausch Health Companies Inc. remains a pivotal player in the healthcare landscape, dedicated to enhancing patient health with innovative solutions across various fields, including gastroenterology and dermatology. Through its ongoing commitment to research and development, Bausch Health aspires to solidify its role as a trusted provider in the global healthcare sector.

In conclusion, as ARESTIN celebrates 25 successful years, its legacy reflects not just a milestone but a foundation upon which future innovations in dental health can be built, catering to the needs of countless patients around the world.